| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Baxter International Inc.$22.62
+0.16 (+0.71%)
B 74Pipeline Score MedTech · Commercial
Market Cap
9.65 B
EPS
-1.95
P/E Ratio
-9.57 $
Value Trade
85.11 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.70 B
R&D Expenses
139.00 M
Operating CF
213.00 M
Total Assets
19.85 B
Total Liabilities
13.83 B
Equity
6.04 B
D/E Ratio
12,345
8.61 %
Week
1.97 %
1 Month
-10.79 %
3 Month
9.1 %
6 Month
-76.91 %
5 Year
1,310 %
All Time
Cash Data
Cash Position
2.02 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
3.10 M
52 Week Range
15.73 - 32.04
% held by Insiders
0.95 %
% held by Institutions
105.17 %
Enterprise Value
17.29 B
Total Shares
516.25 M
Short %
8.15 %
Float Shares
512.12 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Baxter International Inc.
222Total events
2Upcoming
48Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 220
Q3 2026
▲Product LaunchPost-Market
AAT XR expected to be available in US early in 2H 2026
spine surgerysource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
May 13, 2026
May 2026
◆Management ChangeCorporate
William Ampofo to become Quality and Regulatory Compliance Committee Chair
Apr 14, 2026
Apr 14, 2026
Apr 13, 2026
Mar 16, 2026
Drug Pipeline Intelligence
B74
Pipeline Score $26.5B
Pipeline ValueValuation Signal
39
Drugs Scored9.2x
rNPV / MCap Top 95%
Small Cap (rank 47 of 911)
Percentile RankBaxter International Inc. holds a solid B-grade pipeline (74/100), with $40.7B risk-adjusted pipeline value, led by Dianeal in End Stage Renal Disease (ESRD) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dianeal Small molecule | ESRD | Phase 3 | NCT00567398 | 58% | $10.1B | COMPLETED | 43 | - | - | Jul 1, 2011 | - | Jul 22, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BAX▲ +0.7%today
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. will conduct a conference call on July 30, 2026, to discuss its second-quarter financial results. The call is scheduled for 7:30 a.m. Central Time and will be accessible via pre-registration. Investors can also listen to the call through Baxter's website.
Read more →BAXBaxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
Baxter has released its 2025 Sustainability Report, which outlines a refreshed strategy aimed at enhancing its commitment to sustainability. The report emphasizes the company's ongoing efforts to create a meaningful impact in the biopharma sector. Specific details about the initiatives and goals were not disclosed in the article.
Read more →BAXBaxter Reports First-Quarter 2026 Results
Baxter International Inc. reported its first-quarter 2026 results, showing a 3% increase in worldwide sales but a 4% decline in U.S. sales. The company experienced a net loss of $17 million from continuing operations, with adjusted earnings per share down 35% year-over-year. Despite challenges, Baxter is focusing on stabilizing its business and has introduced new products to enhance patient care.
Read more →BAXBAXTER REPORTS FIRST-QUARTER 2026 RESULTS Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis 1,2 U.S. GAAP 3 diluted earnings per s
Baxter International Inc. reported first-quarter 2026 results with sales from continuing operations of $2.7 billion, reflecting a 3% increase on a reported basis but a 1% decline on an organic basis. The U.S. saw a decrease of 4% in sales, contrasting with international sales, which rose 12%. The adjusted diluted earnings per share decreased by 35% from the previous year, prompting the company to reiterate its financial outlook for the year. Overall, the results align with the company's expectations but highlight ongoing challenges in stabilizing certain segments of the business.
Read more →BAXBaxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
Baxter International Inc. is showcasing innovative surgical solutions at the AORN Global Surgical Conference & Expo 2026. Key highlights include the AAT XR spine surgical table and the Dynamo Series smart stretcher, designed to enhance efficiency and patient safety. These innovations reflect Baxter's commitment to improving care delivery and outcomes in surgical settings.
Read more →BAXBaxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
Baxter recently participated in the AORN Global Surgical Conference & Expo 2026, showcasing its latest innovations. The event highlighted advancements in surgical technologies and practices. Further details about specific products or innovations were not provided in the article.
Read more →BAXBaxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. announced that it will host a conference call to discuss its financial results for the first quarter of 2026. The call is aimed at investors and will provide insights into the company's performance during that period. Further details regarding the timing and access to the call were not provided.
Read more →BAXBaxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
Baxter has announced the introduction of the IV Verify Line Labeling System, aimed at enhancing IV labeling processes in healthcare settings. This automated solution is designed to improve accuracy and efficiency in patient care. The initiative reflects Baxter's commitment to innovation in healthcare technology.
Read more →BAXBaxter to Host Annual Meeting of Stockholders in Virtual Format
Baxter International Inc. will conduct its 2026 Annual Meeting of Stockholders virtually on May 5, 2026, starting at 9 a.m. Central Time. Stockholders can access the meeting online and are encouraged to vote their shares in advance. Questions can be submitted before and during the meeting, with answers provided afterward if time constraints prevent live responses.
Read more →BAXExecutive Summary Management and Board of Directors Andrew Hider appointed as President and CEO following a robust search process overseen by a CEO Search Working group consisting of independent directors and conducted w
Baxter International has appointed Andrew Hider as President and CEO, following a thorough search process led by independent directors. This move includes the separation of the CEO and Chair roles to enhance leadership focus. The company has also made significant progress in board refreshment and sustainability initiatives to adapt to changing market dynamics. Overall, the changes are positioned to better align Baxter's leadership with its mission and future goals.
Read more →BAXBaxter Announces CFO Transition
Baxter International Inc. announced the departure of CFO Joel Grade, who will remain in an advisory role until April 30, 2026. Anita Zielinski has been appointed as interim CFO while the company searches for a permanent replacement. Baxter reiterated its financial outlook for 2026, emphasizing its commitment to stability and value creation.
Read more →BAXBAXTER ANNOUNCES CFO TRANSITION Joel Grade to depart as Baxter CFO; Anita Zielinski named interim CFO DEERFIELD, Ill., MARCH 16, 2026 - Baxter International Inc. (NYSE:BAX), a global medtech leader,
Baxter International Inc. has announced the departure of Chief Financial Officer Joel Grade, who is leaving to focus on family matters but will remain in an advisory role until the end of April 2026. Anita Zielinski has been named as the interim CFO and brings significant experience from her previous roles. The company is committed to maintaining its full-year 2026 financial outlook despite this leadership change. Baxter’s president expressed confidence in the finance team to ensure stability during this transition.
Read more →BAX▲ +5.8%on this news
BAXTER REPORTS FOURTH-QUARTER 2025 RESULTS Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis 1,2 Fourth-quarter U.S. GA
Baxter International Inc. reported its fourth-quarter 2025 results, highlighting an overall sales increase of 8% to $2.97 billion. However, the company did not meet its expectations, reflected in a significant net loss and a drop in adjusted earnings per share. The CEO emphasized the importance of ongoing improvements and the introduction of a new operating model aimed at enhancing performance. Despite these challenges, Baxter continues to focus on innovation and strategic priorities, including launching new medical devices.
Read more →BAX▼ -16%on this newsshared move
Baxter Reports Fourth-Quarter 2025 Results
Baxter International Inc. reported its fourth-quarter 2025 results, indicating sales growth across all segments, though the results fell short of expectations. CEO Andrew Hider emphasized the importance of a new operating model aimed at improving performance and customer engagement. The company also announced board changes and plans for an earnings conference call to discuss results and future outlook.
Read more →BAXBaxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors
Baxter International Inc. will hold a conference call on February 12, 2026, to discuss its fourth-quarter financial results for 2025. The call is set for 7:30 a.m. Central Time and will be accessible via a pre-registration link. Additionally, the call will be webcast on Baxter's website, emphasizing the company's commitment to transparency with investors.
Read more →BAXBaxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched...
Baxter Healthcare has reported positive reception for its room temperature Hemopatch Sealing Hemostat in Australia and New Zealand. Launched earlier this summer, the product has been embraced by surgical teams for its convenience, versatility, and effective clinical performance. This growing success highlights the product's potential impact in surgical settings.
Read more →BAXBaxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings
Baxter International Inc. announced the upcoming U.S. launch of the Dynamo Series stretcher at the 2026 J.P. Morgan Healthcare Conference. This innovative stretcher is designed to reduce the physical and cognitive burdens on care teams while enhancing patient safety and comfort. It will be available for order in the U.S. and is expected to launch in the first half of 2026.
Read more →BAXBaxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity
Baxter International presented data at the ASHP 2025 Midyear Clinical Meeting, highlighting the benefits of smart infusion pump integration with electronic medical records (EMRs). The analysis of over one million infusions showed improvements in patient safety and clinician productivity. This collaboration with UTMB Health emphasizes the importance of technology in enhancing healthcare delivery.
Read more →BAXBaxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
Baxter International Inc. has announced the early tender results for its cash tender offers for 2.600% senior notes due 2026 and 1.915% senior notes due 2027. The company plans to accept valid tenders before the early tender date and will make payments on the early settlement date. However, due to demand, acceptance of the 2027 Notes will occur on a pro rata basis, and the total consideration will be determined shortly.
Read more →BAXBAXTER ANNOUNCES INCREASE IN MAXIMUM TENDER CAP FOR 1.915% SENIOR NOTES DUE 2027
Baxter International Inc. has raised the maximum purchase price for its 1.915% Senior Unsecured Notes due 2027 from $300 million to $600 million as part of its ongoing cash tender offer. This decision relates to a previously announced offer impacting a total of $1.45 billion in notes. The company has retained the terms of its cash tender offer for 2.600% Senior Unsecured Notes due 2026. Various financial firms are managing the tender offers, and Baxter assures investors of the terms through the Offer to Purchase documentation.
Read more →BAXBAXTER ANNOUNCES TENDER OFFERS FOR 2026 NOTES AND 2027
Baxter International Inc. has announced the commencement of tender offers for its 2026 and 2027 notes, designed to purchase these debt securities for cash. The offers, which are contingent on market conditions, will be funded partly through proceeds from a concurrent offering of senior unsecured notes. Baxter aims to repay existing debts, including a term loan, using the remaining proceeds. These tender offers are set to expire on December 18, 2025.
Read more →BAX▼ -14.5%on this news
BAXTER REPORTS THIRD-QUARTER 2025 RESULTS Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis 1,2 Third-quarter U.S. GAAP
Baxter International Inc. reported its third-quarter 2025 results, showing a 5% increase in sales from continuing operations to $2.84 billion. Adjusted earnings per share reached $0.69, up 41% from the previous year, despite a net loss of $51 million on a U.S. GAAP basis. The company’s performance was bolstered by strong international sales, although domestic sales faced a slight decline. CEO Andrew Hider emphasized ongoing efforts for improvement and the launch of new initiatives to support growth.
Read more →BAXBaxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring adapted workflows and...
Baxter has launched the Hemopatch Sealing Hemostat in New Zealand, following its global introduction in Europe. This room-temperature collagen pad is designed for hemostasis and sealing in both open and minimally invasive surgeries. Clinical visits led by Professor Ulrich Stock highlighted its potential to improve patient outcomes by reducing blood loss and enhancing recovery times.
Read more →BAXDes chirurgiens se réunissent à un symposium à Vienne pour découvrir l'hémostat d'étanchéité HEMOPATCH de Baxter Une confiance qui dure depuis plus d'une décennie. Depuis plus d'une décennie, l'hémostat d'étanchéité Hemopatch est un compagnon de confiance dans...
Baxter's Hemopatch has established itself as a reliable hemostatic agent in surgical procedures worldwide for over ten years. The product is recognized for its critical support and precision in challenging surgical conditions. Baxter continues to showcase Hemopatch at symposiums, highlighting its evolution with the healthcare landscape.
Read more →BAXChirurgen treffen sich auf dem Wiener Symposium, um Baxters HEMOPATCH Sealing Hemostat kennenzulernen Seit über einem Jahrzehnt vertrauenswürdig. Seit über einem Jahrzehnt ist der Hemopatch Sealing Hemostat ein zuverlässiger Begleiter bei Operationen...
Baxter's HEMOPATCH Sealing Hemostat has been a trusted tool in surgeries for over ten years. It provides essential support and precision in high-pressure situations. The product continues to adapt and improve in line with advancements in the healthcare sector.
Read more →BAXChirurgové se sešli na sympoziu ve Vídni, aby se seznámili s hemostatickou a těsnicí náplastí HEMOPATCH od společnosti Baxter Důvěra budovaná více než deset let Už více než deset let je hemostatická a těsnící náplast Hemopatch spolehlivým prostředkem k zastavení krvácení a...
Baxter introduced a new version of its Hemopatch hemostatic and sealing patch at a symposium in Vienna. This updated product can now be stored at room temperature, enhancing its usability in surgical settings. The development reflects over a decade of collaboration with surgeons, addressing real clinical needs. Feedback from users highlights significant improvements in operational efficiency during procedures.
Read more →BAXChirurgovia sa stretli na Viedenskom sympóziu, aby si vyskúšali tesniace hemostatikum HEMOPATCH značky Baxter DEERFIELD, Illinois, 18. august 2025 /PRNewswire/ – Dôveryhodnosť už viac ako desaťročie. Už viac ako desať rokov je tesniace hemostatikum Hemopatch...
Baxter's Hemopatch has been a reliable hemostatic aid for over ten years, providing essential support during surgeries worldwide. The product is noted for its precision under pressure and continues to evolve with healthcare settings. Its longstanding trustworthiness highlights its importance in surgical procedures.
Read more →BAXCirujanos se reúnen en el Simposio de Viena para experimentar el hemostato de sellado HEMOPATCH de Baxter Más de una década de confianza. Durante más de una década, el hemostato de sellado Hemopatch ha sido un compañero de confianza en cirugías de todo el ...
Baxter's Hemopatch has been a reliable hemostatic sealant in surgeries worldwide for over ten years. The product is known for its critical support and precision, adapting to the evolving medical care landscape. Surgeons gathered in Vienna to discuss its ongoing impact and effectiveness in surgical procedures.
Read more →BAXХирурги собрались на Венском симпозиуме, чтобы испытать герметизирующее гемостатическое изделие HEMOPATCH от Baxter Нам доверяют уже более десяти лет Уже более десяти лет герметизирующее гемостатическое изделие Hemopatch является надежным помощником хирургов во...
Baxter's Hemopatch has gained the trust of surgeons worldwide for over a decade. This surgical product is noted for its effectiveness in providing essential support and precision during operations. As it continues to evolve, Hemopatch remains a vital tool in the medical field, ensuring patient safety and improved surgical outcomes.
Read more →BAXChirurdzy obecni na sympozjum w Wiedniu mieli okazję przekonać się o możliwościach nowego hemostatyku uszczelniającego HEMOPATCH firmy Baxter Ponad dekada zaufania. Już od ponad dekady chirurdzy na całym świecie korzystają z hemostatyku uszczelniającego Hemopatch. To zaufany produkt, który...
Baxter's HEMOPATCH has been a trusted hemostatic sealant for over a decade, providing essential support and precision for surgeons globally. The product adapts to the evolving healthcare landscape, ensuring its relevance and effectiveness in various surgical settings. Its proven reliability has made it a staple in surgical procedures.
Read more →BAXSurgeons Convene at Vienna Symposium to Experience Baxter's HEMOPATCH Sealing Hemostat Trusted for Over a Decade. For over a decade, Hemopatch sealing hemostat has been a trusted companion in surgeries worldwide, providing critical...
The Hemopatch sealing hemostat, trusted for over a decade, continues to play a vital role in surgeries globally. Surgeons gathered at a symposium in Vienna to experience its capabilities. The product is recognized for its reliability and adaptability in the evolving healthcare environment.
Read more →BAX▼ -22.4%on this news
BAXTER REPORTS SECOND-QUARTER 2025 RESULTS Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company'
Baxter International Inc. reported second-quarter sales of $2.81 billion, reflecting a 4% increase compared to the previous year. The company maintained its earnings guidance, reporting adjusted diluted EPS of $0.59, a 28% rise from the prior year. The recent appointment of Andrew Hider as CEO is intended to drive innovation and growth. Despite positive results overall, challenges such as a decline in U.S. operational sales and softness in IV solutions were noted.
Read more →BAXBAXTER APPOINTS ANDREW HIDER CHIEF EXECUTIVE OFFICER DEERFIELD, Ill., JULY 7, 2025 Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as p
Baxter International Inc. has appointed Andrew Hider as its new President and CEO, effective no later than September 3, 2025. Hider, who has served as CEO of ATS Corporation since 2017, is noted for successfully optimizing the company's portfolio and achieving significant revenue growth. His extensive experience in diverse industries is expected to help Baxter accelerate innovation and enhance performance as it seeks to redefine healthcare delivery and drive long-term growth. Brent Shafer, the interim CEO, will transition to an independent chair of the Board.
Read more →BAXBaxter launches HEMOPATCH Sealing Hemostat, a room-temperature collagen pad approved for Hemostasis and Sealing, suitable for open surgery and minimally invasive surgical procedures (MIS) "Hemopatch Sealing Hemostat represents a significant development from Baxter, and introducing the room-temperature variant highlights our ongoing...
Baxter has launched the Hemopatch Sealing Hemostat, a new room-temperature collagen pad designed for hemostasis and sealing in both open and minimally invasive surgical procedures. This innovation builds on Baxter's decade of market success and emphasizes the company's commitment to advancing tissue management solutions. The product also features an extended shelf life of three years.
Read more →BAXBaxter bringt HEMOPATCH Sealing Hemostat auf den Markt, ein bei Raumtemperatur verwendbares Kollagenpflaster, das für die Blutstillung und Versiegelung zugelassen ist und sich für offene Operationen und minimalinvasive chirurgische Eingriffe (MIS) eignet „Hemopatch Sealing Hemostat ist eine bedeutende Entwicklung von Baxter, und die Einführung der Variante für Raumtemperatur unterstreicht unser...
Baxter has launched the Hemopatch Sealing Hemostat, a collagen patch approved for hemostasis and sealing in open and minimally invasive surgeries. This new variant can be stored at room temperature and boasts a shelf life of three years. The introduction reflects Baxter's ongoing commitment to innovation in tissue management.
Read more →BAXBaxter uvádza na trh HEMOPATCH: Vstrebateľné kolagénové hemostatikum skladovateľné pri izbovej teplote, schválené na hemostázu a uzatváranie rán pri otvorených aj minimálne invazívnych zákrokoch (MIS). DEERFIELD, Illinois, 20. máj 2025 /PRNewswire/ – „Tesniace hemostatikum Hemopatch od spoločnosti Baxter predstavuje významný pokrok vo variante...
Baxter has launched Hemopatch, a room temperature-stored hemostatic sealant. This product marks a significant advancement in tissue management, boasting a shelf life of three years. Steve Wallace, president of advanced surgery at Baxter, emphasized the company's commitment to innovation in this field. Hemopatch aims to enhance outcomes in both open and minimally invasive surgeries.
Read more →BAXBaxter lance l'hémostat d'étanchéité HEMOPATCH, un tampon de collagène à température ambiante approuvé pour l'hémostase et l'étanchéité, adapté à la chirurgie ouverte et aux procédures chirurgicales mini-invasives « L'hémostat d'étanchéité Hemopatch représente un développement significatif de Baxter, et l'introduction de la variante à température ambiante...
Baxter has launched Hemopatch, an ambient temperature hemostatic patch designed for hemostasis and sealing. This product marks a significant advancement for the company and reflects its commitment to innovation in tissue management. Hemopatch is suitable for both open and minimally invasive surgical procedures.
Read more →BAXBaxter lanza el hemostático sellador HEMOPATCH, una almohadilla de colágeno para hemostasia y sellado "El hemostático sellador Hemopatch representa un avance significativo de Baxter, y la introducción de la versión a temperatura ambiente pone de...
Baxter has launched HEMOPATCH, a collagen-based hemostatic sealant approved for hemostasis and sealing during open and minimally invasive surgeries. This new version can be stored at room temperature and boasts a shelf life of three years, marking a significant advancement in tissue management. Steve Wallace, president of Advanced Surgery at Baxter, emphasized the company's commitment to innovation.
Read more →BAXBaxter выпускает гемостатический пластырь HEMOPATCH, коллагеновую накладку комнатной температуры, одобренную для гемостаза и герметизации, подходящую для открытой хирургии и минимально инвазивных хирургических процедур (MIS) «Гемостатический пластырь Hemopatch представляет собой значительную разработку компании Baxter, и внедрение варианта с комнатной температурой...
Baxter has launched Hemopatch, a hemostatic patch designed for effective sealing and hemostasis during surgical procedures. This innovative product can be stored at room temperature for up to three years, enhancing its usability. The introduction of Hemopatch highlights Baxter's ongoing commitment to advancing surgical technologies and improving patient outcomes.
Read more →BAXSpolečnost Baxter uvádí HEMOPATCH Sealing Hemostat, kolagenový polštářek pro hemostázu a uzavření ran při pokojové teplotě, který je vhodný pro otevřené operace a minimálně invazivní chirurgické zákroky DEERFIELD, Ill., 20. května 2025 /PRNewswire/ – „Výrobek Hemopatch Sealing Hemostat představuje významný úspěch společnosti Baxter. Uvedením varianty ...
Baxter has launched the Hemopatch Sealing Hemostat, a collagen-based hemostat designed for hemostasis and wound closure during open and minimally invasive surgeries. This new variant can be stored at room temperature, reflecting Baxter's commitment to innovation in tissue healing. The product also boasts an extended shelf life of three years.
Read more →BAXBaxter wprowadza hemostatyk uszczelniający HEMOPATCH, opatrunek kolagenowy przeznaczony do przechowywania w temperaturze pokojowej, zatwierdzony do stosowania w celu zatrzymania krwawienia i uszczelnienia rany, odpowiedni do zabiegów otwartych i minimalnie inwazyjnych "Hemostatyk uszczelniający Hemopatch stanowi ważną innowację firmy Baxter, a wprowadzenie wariantu do przechowywania w temperaturze pokojowej...
Baxter has introduced Hemopatch, a collagen-based hemostatic dressing that can be stored at room temperature for up to three years. This product is designed for use in both open and minimally invasive surgeries, highlighting Baxter's commitment to innovation in tissue management. The new storage capability enhances its convenience for healthcare providers.
Read more →BAXBAXTER REPORTS FIRST-QUARTER 2025 RESULTS First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously is
Baxter International Inc. announced its first-quarter 2025 financial results, reporting sales of $2.63 billion, a 5% increase compared to the previous year, and exceeding its own sales guidance. The adjusted diluted EPS for the quarter reached $0.55, performing better than the expected range. Baxter anticipates adjusted diluted EPS for the full year to be between $2.47 and $2.55, with ongoing growth expected across its segments despite some international sales challenges. The company continues to focus on innovation and operational efficiency to drive its mission of saving and sustaining lives.
Read more →BAXSTOCKHOLDER ENGAGEMENT 1 Baxter International Inc. March 2025 SA F E HA R BO R STAT EMENT 2Baxter International This presentation includes forward-looking statements concerning the company's financial results (including
Baxter International Inc. has released its stockholder engagement presentation for March 2025, highlighting various strategic actions and financial outlooks. The company is focused on integrating acquired businesses and managing associated personnel and operational challenges. However, Baxter faces substantial risks, including regulatory hurdles and potential impacts from global economic conditions. Significant management changes have occurred, indicating a shift in leadership as the company adapts to its evolving environment.
Read more →BAX▲ +8.5%on this news
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceed
Baxter International Inc. reported its financial results for the fourth quarter and full year of 2024, showing a modest sales increase that exceeded prior guidance. The sale of its Kidney Care business, finalized for approximately $3.4 billion, marks a significant milestone in Baxter's strategic transformation. Adjusted diluted earnings per share for the fourth quarter also surpassed expectations, indicating operational improvements. Despite these successes, the company reported losses on a U.S. GAAP basis for both the quarter and full year, highlighting ongoing challenges in specific segments.
Read more →BAXUNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On
Baxter International Inc. completed the sale of its Kidney Care business, Vantive, to Carlyle Group for $3.80 billion on January 31, 2025. This transaction has resulted in net cash proceeds estimated at $3.4 billion, with Vantive accounted for as a discontinued operation. Additionally, several transition agreements were established to facilitate the transition process post-sale, which affects Baxter's financial results as reported. The unaudited pro forma financial information reflects these adjustments and portrays the company's financials as if the transaction had occurred earlier.
Read more →BAXBAXTER ANNOUNCES CEO RETIREMENT AND APPOINTMENT OF COO Jos (Joe) E. Almeida to retire as Chair, President and Chief Executive Officer Lead Independent Director Brent Shafer appointed Chair and Interim CEO Board has initi
Baxter International Inc. has announced the immediate retirement of CEO Jos (Joe) E. Almeida, with Brent Shafer appointed as interim CEO. Shafer will lead the search for a permanent CEO while also serving as chair of the board. This transition follows Almeida's nine-year tenure, which included significant strategic shifts and the recent divestment of Baxter's Kidney Care business. The company remains focused on its financial objectives for 2025 despite potential impacts from new U.S. tariffs.
Read more →BAXBAXTER REPORTS THIRD-QUARTER 2024 RESULTS Baxter third-quarter 2024 sales totaled $3.85 billion 1 Third-quarter total Baxter U.S. GAAP 2 diluted earnings per share (EPS) were $0.27 1 adjusted total
Baxter International Inc. reported strong financial results for the third quarter of 2024, with total sales reaching $3.85 billion and adjusted earnings per share of $0.80, surpassing guidance. Despite achieving growth in all segments, including Medical Products Therapies and Kidney Care, the company faces challenges from the recent impact of Hurricane Helene, which temporarily halted production at its North Cove facility. As recovery efforts progress, Baxter aims to ensure supply continuity while managing the expected short-term financial impacts. The ongoing transformation of the company is highlighted by the pending sale of its Kidney Care business.
Read more →BAXSUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION N o v e m b e r 7 , 2 0 24 1 2 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures that are not calculated in accordance with U.S. GAAP (General
Baxter International Inc. has released supplemental historical financial information that includes non-GAAP measures for a clearer understanding of its performance. The company intends to sell its Kidney Care division, which has been categorized as a discontinued operation, impacting financial reporting moving forward. Adjustments have been made to reflect these changes, and special items related to organizational optimization and regulatory compliance costs are noted within its financial results. This presentation aims to enhance transparency for stakeholders regarding Baxter's operational performance amid evolving business dynamics.
Read more →BAXBAXTER PROVIDES UPDATE ON NORTH COVE, N.C., FACILITY AND HURRICANE HELENE RELIEF PLANS FOR COMMUNITY Baxter's North Cove facility affected by flooding and currently closed for production as the comp
Baxter International has provided an update on the impact of Hurricane Helene on its North Cove facility in North Carolina, which is currently closed due to flooding. The company is collaborating with regulatory and local authorities to assess damages and resume production while managing potential supply disruptions. Additionally, the Baxter International Foundation is donating $1.5 million to support recovery efforts in affected communities. Financial impacts from the shutdown are anticipated, with further updates expected during the third quarter earnings announcement.
Read more →BAXBAXTER APPOINTS JEFFREY A. CRAIG TO ITS BOARD Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience DEERFIELD, Ill., SE
Baxter International Inc. has appointed Jeffrey A. Craig to its board of directors, effective September 9, 2024. Mr. Craig, who previously served as the executive chair and CEO of Meritor Corporation, will join the Audit Committee, increasing the board's membership to 12. His extensive background in finance and operations is anticipated to enhance the board's overall expertise and governance.
Read more →BAX▼ -6.6%on this news
BAXTER ANNOUNCES DEFINITIVE AGREEMENT TO DIVEST ITS VANTIVE KIDNEY CARE SEGMENT TO CARLYLE FOR $3.8 BILLION Establishes Vantive as a leading standalone kidney care business backed by Carlyle s global investment team and
Baxter International Inc. has agreed to sell its Kidney Care segment, Vantive, to Carlyle for approximately $3.8 billion, aiming to enhance its strategic focus. This move is part of Baxter's initiatives to create shareholder value and streamline operations. Following the sale, Baxter plans to use the proceeds to reduce debt and invest in higher-growth sectors. The transaction is anticipated to close in late 2024 or early 2025, subject to regulatory approvals.
Read more →BAX▲ +6.6%on this news
BAXTER REPORTS SECOND-QUARTER 2024 RESULTS Second-quarter sales from continuing operations of $3.81 billion increased 3% on a reported basis and 4% on a constant currency basis, exceeding the compan
Baxter International Inc. reported its second-quarter 2024 results with sales from continuing operations reaching $3.81 billion, which represented a 3% increase on a reported basis and a 4% increase on a constant currency basis. The adjusted diluted earnings per share was $0.68, exceeding previous guidance, although GAAP earnings per share reflected a loss. Additionally, Baxter has raised its full-year sales and earnings outlook. The results indicate growth across all segments, despite facing some financial setbacks related to goodwill impairment.
Read more →BAXBaxter's Helion System Launches in Thailand, Bringing Comprehensive Simplicity to ORs Baxter International Inc. (NYSE: BAX), a global MedTech leader, announced the launch of the Helion Integrated Surgical System in Thailand. Leveraging ...
Baxter International Inc. has launched the Helion Integrated Surgical System in Thailand, aiming to enhance operating room efficiency. The system integrates multiple functions into a single device, reducing distractions and improving communication among surgical teams. This initiative aligns with Thailand's healthcare goals to provide better care through advanced technology.
Read more →BAXBAXTER ANNOUNCES MISSION AND LOGO FOR PROPOSED KIDNEY CARE COMPANY VANTIVE Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies...
Baxter International Inc. has announced the mission and logo for its upcoming kidney care company, Vantive, which will focus on therapies for acute and chronic kidney diseases. The mission, 'Extending Lives, Expanding Possibilities,' emphasizes a commitment to improving healthcare experiences. Vantive's branding reflects its innovative approach and will officially launch following the separation from Baxter, expected in late 2024.
Read more →BAX▼ -8.5%on this news
BAXTER REPORTS FIRST-QUARTER 2024 RESULTS First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company'
Baxter International Inc. reported first-quarter 2024 sales of $3.59 billion, reflecting a 2% increase on a reported basis and 3% at constant currency, surpassing prior guidance. The company recorded adjusted diluted EPS of $0.65, also exceeding expectations. Key growth drivers were the Pharmaceuticals segment, which achieved double-digit growth, while the Healthcare Systems Technologies segment experienced challenges. Baxter is working on a potential separation of its Kidney Care business, expecting completion in the second half of 2024.
Read more →BAXBAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis 1 Fourt
Baxter International Inc. reported a strong financial performance for the fourth quarter and full year of 2023, with sales from continuing operations reaching $3.89 billion, a 4% increase. The company announced a proposed separation of its Kidney Care segment, which is expected to create value and enhance growth. Despite a reported full-year loss of $0.15 per share from continuing operations, Baxter's strategic initiatives and improvement in the macroeconomic environment position the company favorably for future growth. The performance reflects strong demand across several of its product segments.
Read more →BAXBAXTER REPORTS THIRD-QUARTER 2023 RESULTS Third-quarter revenue from continuing operations of $3.71 billion increased 3% on a reported basis and 2% on a constant currency basis, ahead of the company
Baxter International Inc. reported a third-quarter revenue of $3.71 billion, marking a 3% increase on a reported basis and exceeding prior guidance. The company's adjusted earnings per share from continuing operations also surpassed expectations, reflecting improved sales and operational efficiencies. Additionally, Baxter completed the divestiture of its BioPharma Solutions business to streamline its operations, while preparations for a spinoff of its Kidney Care segment are underway, expected by July 2024.
Read more →BAXBAXTER ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS Addition of Stephen H. Rusckowski complements and expands current board expertise with deep healthcare industry and public company board experience
Baxter International Inc. has appointed Stephen H. Rusckowski to its board of directors, enhancing the board's healthcare expertise. Rusckowski, former CEO of Quest Diagnostics, joins effective immediately and will serve on two key committees. The announcement also includes the resignation of Michael Mahoney, who has served on the board for nearly eight years. This transition is aimed at advancing Baxter's strategic growth and operational performance.
Read more →BAX▼ -7.1%on this news
BAXTER REPORTS SECOND-QUARTER 2023 RESULTS Second-quarter revenues increased 3% on a reported basis and 4% on a constant currency basis, ahead of the company's previously issued guidance 1 Second-qu
Baxter International Inc. reported its second-quarter 2023 results, indicating a 3% increase in revenues, which surpassed prior guidance. However, the company reported a GAAP loss of $141 million and adjusted EPS below last year's figures. The quarter's performance was buoyed by various product segments, although revenues from Patient Support Systems saw a decline. Additionally, Baxter is in the process of divesting its BioPharma Solutions business and spinning off its Kidney Care global business, expected to enhance strategic focus moving forward.
Read more →BAXSAF E H AR B O R S TAT E M E N T 2Baxter International This presentation includes forward-looking statements concerning the company's financial results, business development and regulatory activities (including anticipat
Baxter International Inc. presented forward-looking statements concerning its financial results and regulatory activities, highlighting significant strategic initiatives, including the proposed spinoff of its Renal Care and Acute Therapies product categories. The company faces several risks, including economic uncertainties and regulatory challenges that could affect its operational performance. Additionally, recent appointments to the Board reflect a commitment to diversity and strategic renewal. The engagement also outlines Baxter's focus on innovation and operational efficiency to drive future growth.
Read more →BAXBAXTER APPOINTS WILLIAM AMPOFO TO ITS BOARD Addition of Mr. Ampofo complements and expands current board expertise, reflects focus on continued board refreshment efforts DEERFIELD, Ill., JUNE 29, 20
Baxter International Inc. has appointed William A. Ampofo II to its board of directors, effective immediately. Mr. Ampofo brings significant experience from his leadership roles at Boeing and United Technologies Corporation, particularly in supply chain operations. His appointment increases the board's total to 11 members and aims to enhance the company's operational expertise and governance. Baxter's continued efforts toward board refreshment are exemplified by this strategic addition.
Read more →BAXBaxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter s str
Baxter International Inc. has signed an agreement to divest its BioPharma Solutions business for $4.25 billion to Advent International and Warburg Pincus. This move aims to streamline Baxter's focus and enhance its ongoing transformation. Following the sale, Baxter will use the net proceeds to reduce debt, although the divestiture is expected to slightly dilute earnings per share in the fourth quarter of 2023. The transaction is anticipated to close in late 2023, pending regulatory approvals and other conditions.
Read more →BAXBAXTER REPORTS FIRST-QUARTER 2023 RESULTS First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis 1 First-quarter U.S. GAAP earnings per
Baxter International Inc. reported its first-quarter 2023 financial results, revealing a total revenue of $3.65 billion, which represented a 2% decline on a reported basis but a 2% increase when adjusted for constant currency. The company noted a significant decrease in net income attributable to Baxter, falling 36% year-over-year as a result of several special items affecting results. Baxter remains optimistic about its strategic transformation initiatives and anticipates full-year 2023 sales growth of 1% to 2%. Additionally, the company has announced several new product launches and collaborations aimed at enhancing patient care and operational efficiencies.
Read more →BAX▼ -12.1%on this news
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis 1 Fou
Baxter International Inc. reported its fourth-quarter and full-year 2022 financial results, revealing an increase in quarterly sales to $3.9 billion, up 11%. Notably, full-year sales reached $15.1 billion, up 18%. Despite this growth, the company faced challenges with a GAAP diluted EPS loss of $4.83 for the full year due to impairments. Baxter is strategically moving towards establishing a new operating model and plans to spin off its Renal Care and Acute Therapies businesses to improve operational efficiency and shareholder value.
Read more →BAX▼ -7.8%on this news
BAXTER ANNOUNCES STRATEGIC ACTIONS TO ENHANCE OPERATIONAL EFFECTIVENESS, ACCELERATE INNOVATION FOR PATIENTS AND DRIVE VALUE FOR SHAREHOLDERS Planning to spin off the Renal Care and Acute Therapies global business units i
Baxter International Inc. announced strategic initiatives to enhance its operational effectiveness, including a planned spinoff of its Renal Care and Acute Therapies business units into a standalone entity. This move aims to improve focus and accelerate innovation, while a new operating model is also being established to streamline operations. Baxter is exploring strategic alternatives for its BioPharma Solutions business to further enhance its capital structure. The spinoff and reorganization are anticipated to be completed within the next 12 to 18 months, subject to various regulatory and operational approvals.
Read more →BAX▼ -6.4%on this news
BAXTER REPORTS THIRD-QUARTER 2022 RESULTS Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis 1 Third-
BAXTER REPORTS THIRD-QUARTER 2022 RESULTS Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis1 Third-quarter U.S. GAAP earnings (loss) per share (EPS) were ($5.83) Adjusted EPS total
Read more →BAXFall Stockholder Engagement Baxter International Inc. October 2022 Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results, business development and regulato
Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results, business development and regulatory activities (including the December 2021 acquisition of Hillrom), the anticipated impact of Value Improvement Processes (VIP
Read more →BAX▼ -10.9%on this news
BAXTER REPORTS SECOND-QUARTER 2022 RESULTS Second-quarter revenue of $3.75 billion increased 21% on a reported basis, 26% on a constant currency basis and 3% on an operational basis 1 Second-quarter
BAXTER REPORTS SECOND-QUARTER 2022 RESULTS Second-quarter revenue of $3.75 billion increased 21% on a reported basis, 26% on a constant currency basis and 3% on an operational basis1 Second-quarter U.S. GAAP earnings per share (EPS) totaled $0.50 Adjusted EPS totaled $0.87 Bax
Read more →BAXBAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2022 INVESTOR CONFERENCE Company to share strategy for ongoing growth and innovation aligned with mission to save and sustain lives and vision
BAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2022 INVESTOR CONFERENCE Company to share strategy for ongoing growth and innovation aligned with mission to save and sustain lives and vision to transform healthcare Recent Hillrom acquisition positions Baxter to acceler
Read more →BAXBAXTER REPORTS FIRST-QUARTER 2022 RESULTS First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis 1 First-quarter U.S
BAXTER REPORTS FIRST-QUARTER 2022 RESULTS First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14 Adjusted EPS totaled $0.93 Baxter
Read more →BAXUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 13, 2021, Baxter International Inc. (we, our, or us) announced that we completed the previously announced acquisition of Hill-Rom Holdings, Inc. (Hillrom). The unaudited pro forma condensed combined stateme
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS Fourth-quarter sales of $3.5 bill
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS Fourth-quarter sales of $3.5 billion increased 10% on a reported basis, 12% on a constant currency basis and 4% on an operational basis1 Fourth-quarter U.S. GA
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS THIRD-QUARTER 2021 RESULTS Third-quarter revenue of $3.2 billion increased
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS THIRD-QUARTER 2021 RESULTS Third-quarter revenue of $3.2 billion increased 9% on a reported basis, 7% on a constant currency basis and 6% on an operational basis1 Third-quarter U.S. GAAP earnings per s
Read more →BAXOctober 2021 Baxter International Inc. Fall Shareholder Engagement 2 This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, capital structure, cost s
October 2021 Baxter International Inc. Fall Shareholder Engagement 2 This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, capital structure, cost savings initiatives, R&D pipeline, including results of clin
Read more →BAXBaxter: Lauren Russ, (224) 948-5353 media@baxter.com Hillrom: Howard Karesh, (312) 819-7268 howard.karesh@hillrom.com Investor Contacts Baxter: Clare Trachtman, (224) 948-3020 clare_t
Baxter: Lauren Russ, (224) 948-5353 Hillrom: Howard Karesh, (312) 819-7268 howard.karesh@hillrom.com Baxter: Clare Trachtman, (224) 948-3020 clare_trachtman@baxter.com Hillrom: Mary Kay Ladone, marykay.ladone@hillrom.com BAXTER TO ACQUIRE HILLROM, EXPANDING CONNECTED CARE
Read more →BAX▼ -5.5%on this news
Steve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS SECOND-QUARTER 2021 RESULTS Second-quarter revenue of $3.1 billion increase
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS SECOND-QUARTER 2021 RESULTS Second-quarter revenue of $3.1 billion increased 14% on a reported basis, 9% on a constant currency basis and 8% on an operational basis1 Second-quarter U.S. GAAP earnings p
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS FIRST-QUARTER 2021 RESULTS First-quarter revenue of $2.9 billion increased
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS FIRST-QUARTER 2021 RESULTS First-quarter revenue of $2.9 billion increased 5% on a reported basis and 1% on both a constant currency and operational basis1 First-quarter U.S. GAAP earnings per share (E
Read more →BAXDocument BAXTER INTERNATIONAL INC. Net Sales by Segment (unaudited, in millions) Years Ended December 31, Reported Growth Constant Currency Growth 2020 2019 2018 2020 2019 2020 2019 Net sales by segment Americas $ 6,321
BAXTER INTERNATIONAL INC. Net Sales by Segment (unaudited, in millions) Years Ended December 31, Reported Growth Constant Currency Growth 2020 2019 2018 2020 2019 2020 2019 Net sales by segment Americas $ 6,321 $ 6,306 $ 6,156 0 % 2 %
Read more →BAXStacey Eisen, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER APPOINTS DR. DAVID WILKES TO ITS BOARD AND ALBERT STROUCKEN AS LEAD INDEPENDENT DI
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER APPOINTS DR. DAVID WILKES TO ITS BOARD AND ALBERT STROUCKEN AS LEAD INDEPENDENT DIRECTOR Addition of Dr. Wilkes complements and expands current board expertise Mr. Stroucken's appointment reflects ongoing boa
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS Fourth-quarter sales of $3.2 bill
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS Fourth-quarter sales of $3.2 billion increased 5% on a reported basis, 3% on a constant currency basis and 2% on an operational basis1 Fourth-quarter U.S. GAAP
Read more →BAXth Annual J.P. Morgan Healthcare Conference Jos (Joe) E. Almeida, Chairman & Chief Executive Officer
39th Annual J.P. Morgan Healthcare Conference Jos (Joe) E. Almeida, Chairman & Chief Executive Officer January 11, 2021 2 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's preliminary financial results for fourth-quarter and full-yea
Read more →BAXStacey Eisen, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER ANNOUNCES PROPOSED $650
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER ANNOUNCES PROPOSED $650 MILLION SENIOR NOTES OFFERING DEERFIELD, Ill., Oct. 29, 2020 - Baxter International Inc. (NYSE BAX), a leading global medical products company, today announced that it proposes to offer
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS THIRD-QUARTER 2020 RESULTS Third-quarter sales of $2.97 billion increased 4
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS THIRD-QUARTER 2020 RESULTS Third-quarter sales of $2.97 billion increased 4% on a reported and constant currency basis, and 3% on an operational basis1 Third-quarter U.S. GAAP earnings per share (EPS)
Read more →BAXAugust 2019 Fall Shareholder Engagement Baxter International Inc. October 2020 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, capital allocation activit
Fall Shareholder Engagement Exhibit 99.1 August 2019 Fall Shareholder Engagement Baxter International Inc. October 2020 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, capital allocation activities and principle
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS SECOND-QUARTER 2020 RESULTS Second-quarter revenue of $2.7 billion decrease
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS SECOND-QUARTER 2020 RESULTS Second-quarter revenue of $2.7 billion decreased 4% on a reported basis, 1% on a constant currency basis and 2% on an operational basis1 Second-quarter U.S. GAAP earnings pe
Read more →BAXSafe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, corporate governance goals, compensation program, COVID-19 response effo
Fall Shareholder Engagement August 2019 Baxter International Inc. April 2020 Annual Meeting Shareholder Engagement Exhibit 99.1 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter's financial results, business development activities, c
Read more →BAXSteve Brett, (224) 948-5353 media baxter.com Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS FIRST-QUARTER 2020 RESULTS First-quarter revenue of $2.8 billion increased
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3020 BAXTER REPORTS FIRST-QUARTER 2020 RESULTS First-quarter revenue of $2.8 billion increased 6% on a reported basis and 8% on both a constant currency and operational basis First-quarter U.S. GAAP earnings per share (EP
Read more →BAXStacey Eisen, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS, COMPLETES FINANCIAL RESTATEMENT
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS, COMPLETES FINANCIAL RESTATEMENT PROCESS DEERFIELD, Ill., March 17, 2020 Baxter International Inc. (NYSE:BAX), a leading global medical products company, toda
Read more →BAXStacey Eisen, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER ANNOUNCES PRELIMINARY NET SALES FOR THE FOURTH-QUARTER AND FULL-YEAR 2019 AND ANNO
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER ANNOUNCES PRELIMINARY NET SALES FOR THE FOURTH-QUARTER AND FULL-YEAR 2019 AND ANNOUNCES PRELIMINARY FULL-YEAR 2020 GUIDANCE DEERFIELD, Ill., JANUARY 12, 2020 Baxter International Inc. (NYSE:BAX), a leading g
Read more →BAXStacey Eisen, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-Q
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER RECEIVES NYSE NOTICE REGARDING DELAYED FORM DEERFIELD, Ill., November 22, 2019 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that the New York Stock Exchange
Read more →BAXStacey Eisen, (224) 948-2304 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS PRELIMINARY THIRD QUARTER 2019 OPERATING RESULTS Third quarter net revenue
Stacey Eisen, (224) 948-2304 Clare Trachtman, (224) 948-3085 BAXTER REPORTS PRELIMINARY THIRD QUARTER 2019 OPERATING RESULTS DEERFIELD, Ill., October 24, 2019 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced certain preliminary
Read more →BAXSteve Brett, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2019 RESULTS - Anticipates $500 million investment to suppor
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2019 RESULTS - Anticipates $500 million investment to support Advancing American Kidney Health Initiative - DEERFIELD, Ill., July 25, 2019 Baxter International Inc. (NYSE:BAX), a leadin
Read more →BAXSteve Brett, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2019 RESULTS First-quarter revenue of $2.6 billion declined 2
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2019 RESULTS DEERFIELD, Ill., APRIL 25, 2019 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2019 and incre
Read more →BAXSteve Brett, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-quarter revenue of $2.8 bi
Steve Brett, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS DEERFIELD, Ill., JAN. 31, 2019 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter a
Read more →BAXStacey Eisen, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER APPOINTS PATRICIA MORRISON AND AMY WENDELL TO ITS BOARD Addition of industry veter
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER APPOINTS PATRICIA MORRISON AND AMY WENDELL TO ITS BOARD DEERFIELD, Ill., DECEMBER 6, 2018 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed Patr
Read more →BAXStacey Eisen, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS THIRD-QUARTER 2018 RESULTS AND UPDATES FINANCIAL OUTLOOK FOR FULL-YEAR 201
Stacey Eisen, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS THIRD-QUARTER 2018 RESULTS AND UPDATES FINANCIAL OUTLOOK DEERFIELD, Ill., OCTOBER 31, 2018 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for t
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2018 RESULTS AND INCREASES EARNINGS OUTLOOK FOR FULL-YEAR 201
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2018 RESULTS AND INCREASES EARNINGS OUTLOOK FOR FULL-YEAR 2018 DEERFIELD, Ill., JULY 26, 2018 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today repor
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2018 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2018 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2018 DEERFIELD, Ill., April 26, 2018 Baxter International Inc. (NYSE: BAX) today reported results for the first quarter of 2018
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter Revenue of $2.8 B
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS DEERFIELD, Ill., February 1, 2018 Baxter International Inc. (NYSE:BAX) today reported results for the fourth quarter and full-year ended December 31, 2017, and
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS THIRD-QUARTER 2017 RESULTS AND UPDATES FINANCIAL OUTLOOK FOR FULL-YEAR 201
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS THIRD-QUARTER 2017 RESULTS AND UPDATES FINANCIAL OUTLOOK FOR FULL-YEAR 2017 DEERFIELD, Ill., October 25, 2017 Baxter International Inc. (NYSE:BAX) today reported results for the third quarter of 2017 a
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2017 RESULTS AND PROVIDES UPDATED FINANCIAL OUTLOOK FOR 201
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND-QUARTER 2017 RESULTS AND PROVIDES UPDATED FINANCIAL OUTLOOK FOR 2017 AND 2020 DEERFIELD, Ill., July 26, 2017 Baxter International Inc. (NYSE:BAX) today reported results for the second quarter of
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER APPOINTS CATHY R. SMITH TO ITS BOARD Target CFO Complements Current Board Expertis
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER APPOINTS CATHY R. SMITH TO ITS BOARD Target CFO Complements Current Board Expertise DEERFIELD, Ill., July 17, 2017 Baxter International Inc. (NYSE:BAX) today announced it has appointed Cathy R. Smith, executive
Read more →BAXBill Rader, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2017 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST-QUARTER 2017 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2017 DEERFIELD, Ill., April 26, 2017 Baxter International Inc. (NYSE:BAX) today reported results for the first quarter of 2017 an
Read more →BAXBill Rader, (224) 948-5353 Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER APPOINTS DR. STEPHEN OESTERLE TO ITS BOARD Industry Veteran Complements Current Board Expertise
Bill Rader, (224) 948-5353 Clare Trachtman, (224) 948-3085 BAXTER APPOINTS DR. STEPHEN OESTERLE TO ITS BOARD Industry Veteran Complements Current Board Expertise DEERFIELD, Ill., February 8, 2017 Baxter International Inc. (NYSE:BAX) today announced it has appointed Stephen (S
Read more →BAXStacey Eisen, (224) 948-5353 Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS 2016 FOURTH-QUARTER AND FULL-YEAR RESULTS Fourth-Quarter Revenue of $2.6 Billion Increase
Stacey Eisen, (224) 948-5353 Trachtman, (224) 948-3085 BAXTER REPORTS 2016 FOURTH-QUARTER AND FULL-YEAR RESULTS DEERFIELD, Ill., February 1, 2017 Baxter International Inc. (NYSE:BAX) today reported results for the fourth quarter ended December 31, 2016, and provided its guida
Read more →BAXDeborah Spak, (224) 948-2349 Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS THIRD QUARTER 2016 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Strong Oper
Deborah Spak, (224) 948-2349 Trachtman, (224) 948-3085 BAXTER REPORTS THIRD QUARTER 2016 RESULTS AND INCREASES FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Strong Operational Performance Contributes to Margin Improvement Quarter GAAP Earnings per Share of $0.23; Adjusted Earnings p
Read more →BAXDeborah Spak, (224) 948-2349 Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS SECOND QUARTER 2016 RESULTS AND RAISES FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Strong Operat
Deborah Spak, (224) 948-2349 BAXTER REPORTS SECOND QUARTER 2016 RESULTS AND RAISES FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Strong Operational Performance Across Baxter s Portfolio Contributed to Growth in Second Quarter Second Quarter GAAP Earnings Per Share Were $2.19; Adjuste
Read more →BAXDeborah Spak, (224) 948-2349 Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER REPORTS FIRST QUARTER 2016 RESULTS AND PROVIDES UPDATED FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Posi
Deborah Spak, (224) 948-2349 BAXTER REPORTS FIRST QUARTER 2016 RESULTS AND PROVIDES UPDATED FINANCIAL OUTLOOK FOR FULL-YEAR 2016 Positive Sales Mix and Disciplined Expense Management Contribute to Strong First Quarter Performance Adjusted Earnings Per Share were $0.36; Firs
Read more →Competitive Position
How BAX ranks across every disease it competes inCompetitive Position is a premium feature
See how BAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial